Compounds > l 163191
Page last updated: 2024-09-05

l 163191 and pioglitazone

l 163191 has been researched along with pioglitazone in 1 studies

Compound Research Comparison

Studies
(l 163191)		Trials
(l 163191)		Recent Studies (post-2010)
(l 163191)		Studies
(pioglitazone)		Trials
(pioglitazone)		Recent Studies (post-2010) (pioglitazone)
350174,3388242,277

Protein Interaction Comparison

ProteinTaxonomyl 163191 (IC50)pioglitazone (IC50)
CDGSH iron-sulfur domain-containing protein 1Rattus norvegicus (Norway rat)1
Bile salt export pumpRattus norvegicus (Norway rat)2
Peroxisome proliferator-activated receptor gammaRattus norvegicus (Norway rat)0.7
Bile salt export pumpHomo sapiens (human)0.337
Carbonic anhydrase 2Homo sapiens (human)0.114
Steryl-sulfataseHomo sapiens (human)0.8
Peroxisome proliferator-activated receptor alphaMus musculus (house mouse)1.15
Amine oxidase [flavin-containing] BHomo sapiens (human)0.298
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)3.0379
Peroxisome proliferator-activated receptor gammaMus musculus (house mouse)0.7
CDGSH iron-sulfur domain-containing protein 2Homo sapiens (human)4.8
CDGSH iron-sulfur domain-containing protein 1Homo sapiens (human)8.65

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1

Other Studies

1 other study(ies) available for l 163191 and pioglitazone

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013